Prevention of REnal and Vascular ENd-stage Disease

Overview

Acronym
PREVEND
Investigators
  • Dr. Hans Hillege
    University of Groningen
Contacts
  • Dr. Hans Hillege
    University of Groningen

General Design

Study design
Cohort
Start Year
1997
Recruitment Target
  • Individuals
Number of Participants
8,592
Number of Participants with Biological Samples
8,592
Supplementary Information

Of the 85,421 subjects invited 40,856 responded (=48%) . We invited all consenting subjects with a morning urinary albumin concentration (UAC) of >10 mg/L (n=7,768) and an a-select sample of those with an UAC <10 mg/L (n=3,395) for further studies . Of these invitees 8,592 subjects completed the first screening, that was held in 1997/1998

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Marker Paper

Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. J Am Soc Nephrol. 2000 Oct;11(10):1882-8

PUBMED 11004219

Timeline

Population

PREVEND cohort

Selection Criteria

Minimum age
18
Maximum age
75
Countries
  • Netherlands
Ethnic Origin
  • Caucasian

Sources of Recruitment

General Population
  • Volunteer enrolment

Sample Size

Number of Participants
8,592
Number of Participants with Biological Samples
8,592

Data Collection Events

# Name Description Start End
0 NC1 1997 1998
1 Second screening 2001 2003
2 Third screening 2003 2006
3 Fourth Screening 2009 2012

Individual Studies Included

Acronym Name Study design Participants Countries

Harmonization Projects Included

Acronym Name

Networks

Acronym Name Studies

Datasets

Name Type Data Collection Events Variables
Last Update: 2021-04-12 16:05